<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31896594</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e01921-19</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01921-19</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a causative agent of hand-foot-mouth disease, and it sometimes causes severe neurological disease. Development of effective vaccines and animal models to evaluate vaccine candidates are needed. However, the animal models currently used for vaccine efficacy testing, monkeys and neonatal mice, have economic, ethical, and practical drawbacks. In addition, EV71 strains prepared for lethal challenge often develop decreased virulence during propagation in cell culture. To overcome these problems, we used a mouse model expressing human scavenger receptor B2 (hSCARB2) that showed lifelong susceptibility to EV71. We selected virulent EV71 strains belonging to the subgenogroups B4, B5, C1, C2, and C4 and propagated them using a culture method for EV71 without an apparent reduction in virulence. Here, we describe a novel EV71 vaccine efficacy test based on these hSCARB2 transgenic (Tg) mice and these virulent viruses. Adult Tg mice were immunized subcutaneously with formalin-inactivated EV71. The vaccine elicited sufficient levels of neutralizing antibodies in the immunized mice. The mice were subjected to lethal challenge with virulent viruses via intravenous injection. Survival, clinical signs, and body weight changes were observed for 2&#x2009;weeks. Most immunized mice survived without clinical signs or histopathological lesions. The viral replication in immunized mice was much lower than that in nonimmunized mice. Mice immunized with the EV71 vaccine were only partially protected against lethal challenge with coxsackievirus A16. These results indicate that this new model is useful for <i>in vivo</i> EV71 vaccine efficacy testing.<b>IMPORTANCE</b> The development of new vaccines for EV71 relies on the availability of small animal models suitable for <i>in vivo</i> efficacy testing. Monkeys and neonatal mice have been used, but the use of these animals has several drawbacks, including high costs, limited susceptibility, and poor experimental reproducibility. In addition, the related ethical issues are considerable. The new efficacy test based on hSCARB2 Tg mice and virulent EV71 strains propagated in genetically modified cell lines presented here can overcome these disadvantages and is expected to accelerate the development of new EV71 vaccines.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Imura</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sudaka</LastName><ForeName>Yui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takashino</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Kanami</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Kyousuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Noriyo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Hidekazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Virus Research Center, Clinical Research Division, Sendai Medical Center, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuta</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yamagata Prefectural Institute of Public Health, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan koike-st@igakuken.or.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051907">Lysosomal Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051116">Receptors, Scavenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074299">SCARB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051907" MajorTopicYN="N">Lysosomal Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051116" MajorTopicYN="N">Receptors, Scavenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">animal models</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31896594</ArticleId><ArticleId IdType="pmc">PMC7158731</ArticleId><ArticleId IdType="doi">10.1128/JVI.01921-19</ArticleId><ArticleId IdType="pii">JVI.01921-19</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chong P, Liu CC, Chow YH, Chou AH, Klein M. 2015. Review of enterovirus 71 vaccines. Clin Infect Dis 60:797&#x2013;803. doi:10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL. 2013. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381:2024&#x2013;2032. doi:10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N. 2014. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370:818&#x2013;828. doi:10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, Jiang L, Dong C, Che Y, Huang T, Jiang Z, Xie Z, Wang L, Liao Y, Liang Y, Nong Y, Liu J, Zhao H, Na R, Guo L, Pu J, Yang E, Sun L, Cui P, Shi H, Wang J, Li Q. 2014. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 370:829&#x2013;837. doi:10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, Su IJ, Chong PC, Hsieh SM. 2013. A phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31:2471&#x2013;2476. doi:10.1016/j.vaccine.2013.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.015</ArticleId><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwa SH, Lee YA, Brewoo JN, Partidos CD, Osorio JE, Santangelo JD. 2013. Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine. PLoS Negl Trop Dis 7:e2538. doi:10.1371/journal.pntd.0002538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002538</ArticleId><ArticleId IdType="pmc">PMC3820736</ArticleId><ArticleId IdType="pubmed">24244774</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambyah PA, Oon J, Asli R, Kristanto W, Hwa SH, Vang F, Karwal L, Fuchs J, Santangelo JD, Gordon GS, Thomson C, Rao R, Dean H, Das SC, Stinchcomb DT. 2019. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: a phase I, double blind, randomized, placebo-controlled, study of two dosages. Vaccine 37:4344&#x2013;4353. doi:10.1016/j.vaccine.2019.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.06.023</ArticleId><ArticleId IdType="pubmed">31230881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YC, Hsu JT, Huang JH, Ho MS, Ho YC. 2003. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol Lett 25:919&#x2013;925. doi:10.1023/a:1024071514438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1024071514438</ArticleId><ArticleId IdType="pubmed">12889824</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim PY, Hickey AC, Jamiluddin MF, Hamid S, Kramer J, Santos R, Bossart KN, Cardosa MJ. 2015. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine 33:6017&#x2013;6024. doi:10.1016/j.vaccine.2015.05.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.05.108</ArticleId><ArticleId IdType="pubmed">26271825</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. 2013. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31:3281&#x2013;3287. doi:10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku Z, Liu Q, Wang X, Chen T, Ye X, Li D, Jin X, Huang Z. 2015. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 33:2335&#x2013;2341. doi:10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. 2008. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26:1855&#x2013;1862. doi:10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Yang Y, Chi Y, Yin J, Yan L, Ku Z, Liu Q, Huang Z, Zhou D. 2015. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71. Vaccine 33:5087&#x2013;5094. doi:10.1016/j.vaccine.2015.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.08.016</ArticleId><ArticleId IdType="pubmed">26296491</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou YL, Lin YW, Shao HY, Yu SL, Wu SR, Lin HY, Liu CC, Huang C, Chong P, Chow YH. 2015. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS Negl Trop Dis 9:e0003692. doi:10.1371/journal.pntd.0003692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003692</ArticleId><ArticleId IdType="pmc">PMC4391779</ArticleId><ArticleId IdType="pubmed">25855976</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Wu L, Chen L, Qin Y, Pan Z, Chen M. 2016. Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges. Vaccine 34:4196&#x2013;4204. doi:10.1016/j.vaccine.2016.06.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.06.058</ArticleId><ArticleId IdType="pubmed">27373596</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY. 2006. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8:1671&#x2013;1678. doi:10.1016/j.micinf.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.01.021</ArticleId><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. 2001. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20:895&#x2013;904. doi:10.1016/s0264-410x(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0264-410x(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YI, Song JH, Kwon BE, Kim HN, Seo MD, Park K, Lee S, Yeo SG, Kweon MN, Ko HJ, Chang SY. 2015. Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection. Vaccine 33:6604&#x2013;6610. doi:10.1016/j.vaccine.2015.10.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.103</ArticleId><ArticleId IdType="pubmed">26529069</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou SL, Ying XL, Han X, Sun XX, Jin Q, Yang F. 2015. Characterization of the enterovirus 71 VP1 protein as a vaccine candidate. J Med Virol 87:256&#x2013;262. doi:10.1002/jmv.24018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24018</ArticleId><ArticleId IdType="pubmed">25043151</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. 2007. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5:6. doi:10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai YH, Huang SW, Hsieh WS, Cheng CK, Chang CF, Wang YF, Wang JR. 2019. Enterovirus A71 containing codon-deoptimized VP1 and high-fidelity polymerase as next-generation vaccine candidate. J Virol 93:e02308-18. doi:10.1128/JVI.02308-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02308-18</ArticleId><ArticleId IdType="pmc">PMC6580961</ArticleId><ArticleId IdType="pubmed">30996087</ArticleId></ArticleIdList></Reference><Reference><Citation>In HJ, Lim H, Lee JA, Lee SR, Jin YB, Jeong KJ, Hyeon JY, Yoo JS, Lee JW, Choi YK, Lee SW. 2018. Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys. PLoS One 13:e0202552. doi:10.1371/journal.pone.0202552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0202552</ArticleId><ArticleId IdType="pmc">PMC6168120</ArticleId><ArticleId IdType="pubmed">30278051</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Hwang CS, Yang WS, Tsai DC, Wu SH, Chou AH, Chow YH, Wu SC, Wang JR, Chiang JR, Huang CC, Pan CH, Chong P. 2014. Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques. PLoS One 9:e106756. doi:10.1371/journal.pone.0106756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0106756</ArticleId><ArticleId IdType="pmc">PMC4157806</ArticleId><ArticleId IdType="pubmed">25197967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL. 2012. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30:1305&#x2013;1312. doi:10.1016/j.vaccine.2011.12.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q. 2010. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccin 6:1028&#x2013;1037. doi:10.4161/hv.6.12.12982.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.6.12.12982</ArticleId><ArticleId IdType="pubmed">21150270</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, Na R, Liang Y, Wang L, Li Q. 2011. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29:6269&#x2013;6275. doi:10.1016/j.vaccine.2011.06.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. 2007. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9:1299&#x2013;1306. doi:10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86:2121&#x2013;2131. doi:10.1128/JVI.06103-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Partidos CD, Santangelo JD, Osorio JE. 2013. Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS One 8:e59501. doi:10.1371/journal.pone.0059501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059501</ArticleId><ArticleId IdType="pmc">PMC3602422</ArticleId><ArticleId IdType="pubmed">23527208</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, Shimanuki M, Shitara H, Taya C, Koike S. 2013. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A 110:14753&#x2013;14758. doi:10.1073/pnas.1217563110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15:798&#x2013;801. doi:10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. 2012. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol 86:5686&#x2013;5696. doi:10.1128/JVI.00020-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00020-12</ArticleId><ArticleId IdType="pmc">PMC3347270</ArticleId><ArticleId IdType="pubmed">22438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. 2013. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 87:3335&#x2013;3347. doi:10.1128/JVI.02070-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02070-12</ArticleId><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Sudaka Y, Takashino A, Kobayashi K, Kataoka C, Suzuki T, Iwata-Yoshikawa N, Kotani O, Ami Y, Shimizu H, Nagata N, Mizuta K, Matsuzaki Y, Koike S, Fujii K, Sudaka Y, Takashino A, Kobayashi K, Kataoka C, Suzuki T, Iwata-Yoshikawa N, Kotani O, Ami Y, Shimizu H, Nagata N, Mizuta K, Matsuzaki Y, Koike S. 2018. VP1 amino acid residue 145 of enterovirus 71 Is a key residue for its receptor attachment and resistance to neutralizing antibody during cynomolgus monkey infection. J Virol 92:e00682-18. doi:10.1128/JVI.00682-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00682-18</ArticleId><ArticleId IdType="pmc">PMC6052295</ArticleId><ArticleId IdType="pubmed">29848582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Sudaka Y, Takashino A, Imura A, Fujii K, Koike S, Kobayashi K, Sudaka Y, Takashino A, Imura A, Fujii K, Koike S. 2018. Amino acid variation at VP1-145 of Enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice. J Virol 92:e00681-18. doi:10.1128/JVI.00681-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00681-18</ArticleId><ArticleId IdType="pmc">PMC6052303</ArticleId><ArticleId IdType="pubmed">29848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY, Chou AH, Wang JR, Hsieh SY, Su IJ, Liu CC. 2012. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS One 7:e49973. doi:10.1371/journal.pone.0049973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049973</ArticleId><ArticleId IdType="pmc">PMC3511423</ArticleId><ArticleId IdType="pubmed">23226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H, Nomoto A. 1991. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A 88:951&#x2013;955. doi:10.1073/pnas.88.3.951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.3.951</ArticleId><ArticleId IdType="pmc">PMC50932</ArticleId><ArticleId IdType="pubmed">1846972</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike S, Taya C, Aoki J, Matsuda Y, Ise I, Takeda H, Matsuzaki T, Amanuma H, Yonekawa H, Nomoto A. 1994. Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene&#x2013;influence of the transgene expression on pathogenesis. Arch Virol 139:351&#x2013;363. doi:10.1007/bf01310797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf01310797</ArticleId><ArticleId IdType="pubmed">7832641</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie H, Koike S, Kurata T, Sato-Yoshida Y, Ise I, Ota Y, Abe S, Hioki K, Kato H, Taya C. 1994. Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence. J Virol 68:681&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236503</ArticleId><ArticleId IdType="pubmed">8289371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T, Yoneyama M, Fujita T, Taya C, Yonekawa H, Koike S. 2005. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 79:4460&#x2013;4469. doi:10.1128/JVI.79.7.4460-4469.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.7.4460-4469.2005</ArticleId><ArticleId IdType="pmc">PMC1061561</ArticleId><ArticleId IdType="pubmed">15767446</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe Y, Fujii K, Nagata N, Takeuchi O, Akira S, Oshiumi H, Matsumoto M, Seya T, Koike S. 2012. The toll-like receptor 3-mediated antiviral response is important for protection against poliovirus infection in poliovirus receptor transgenic mice. J Virol 86:185&#x2013;194. doi:10.1128/JVI.05245-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05245-11</ArticleId><ArticleId IdType="pmc">PMC3255933</ArticleId><ArticleId IdType="pubmed">22072781</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe S, Ota Y, Koike S, Kurata T, Horie H, Nomura T, Hashizume S, Nomoto A. 1995. Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice. Virology 206:1075&#x2013;1083. doi:10.1006/viro.1995.1030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1995.1030</ArticleId><ArticleId IdType="pubmed">7856082</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragunsky E, Nomura T, Karpinski K, Furesz J, Wood DJ, Pervikov Y, Abe S, Kurata T, Vanloocke O, Karganova G, Taffs R, Heath A, Ivshina A, Levenbook I. 2003. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study. Bull World Health Organ 81:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572431</ArticleId><ArticleId IdType="pubmed">12764491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, Hsiao KN, Chitra E, Tsou YL, Chang HW, Sia C, Chong P, Chow YH. 2013. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 8:e57591. doi:10.1371/journal.pone.0057591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Liu Q, Wu X, Chen P, Wu X, Guo Y, Liu S, Liang Z, Fan C, Wang Y. 2016. A safe and sensitive enterovirus A71 infection model based on human SCARB2 knock-in mice. Vaccine 34:2729&#x2013;2736. doi:10.1016/j.vaccine.2016.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.04.029</ArticleId><ArticleId IdType="pubmed">27102822</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, Itagaki T, Ohmi A, Okamoto M, Nishimura H, Matsuzaki Y, Hongo S, Sugawara K, Shimizu H, Ahiko T. 2009. Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27:3153&#x2013;3158. doi:10.1016/j.vaccine.2009.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.060</ArticleId><ArticleId IdType="pubmed">19446185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Abiko C, Murata T, Matsuzaki Y, Itagaki T, Sanjoh K, Sakamoto M, Hongo S, Murayama S, Hayasaka K. 2005. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol 43:6171&#x2013;6175. doi:10.1128/JCM.43.12.6171-6175.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.12.6171-6175.2005</ArticleId><ArticleId IdType="pmc">PMC1317214</ArticleId><ArticleId IdType="pubmed">16333123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Abiko C, Aoki Y, Ikeda T, Matsuzaki Y, Hongo S, Itagaki T, Katsushima N, Ohmi A, Nishimura H, Ahiko T. 2013. Molecular epidemiology of Coxsackievirus A16 strains isolated from children in Yamagata, Japan between 1988 and 2011. Microbiol Immunol 57:400&#x2013;405. doi:10.1111/1348-0421.12041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1348-0421.12041</ArticleId><ArticleId IdType="pubmed">23668614</ArticleId></ArticleIdList></Reference><Reference><Citation>Simizu B, Abe S, Yamamoto H, Tano Y, Ota Y, Miyazawa M, Horie H, Satoh K, Wakabayashi K. 2006. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 34:151&#x2013;154. doi:10.1016/j.biologicals.2006.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2006.02.010</ArticleId><ArticleId IdType="pubmed">16679028</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>